➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Moodys
AstraZeneca
Dow
Mallinckrodt

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

MICRODERM Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Microderm patents expire, and when can generic versions of Microderm launch?

Microderm is a drug marketed by J And J and is included in two NDAs.

The generic ingredient in MICRODERM is chlorhexidine gluconate. There are fifty-eight drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the chlorhexidine gluconate profile page.

US ANDA Litigation and Generic Entry Outlook for Microderm

A generic version of MICRODERM was approved as chlorhexidine gluconate by BECTON DICKINSON on October 24th, 1989.

  Start Trial

Summary for MICRODERM
Drug patent expirations by year for MICRODERM
Recent Clinical Trials for MICRODERM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
OHSU Knight Cancer InstituteN/A
National Cancer Institute (NCI)N/A

See all MICRODERM clinical trials

US Patents and Regulatory Information for MICRODERM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J MICRODERM chlorhexidine gluconate SOLUTION;TOPICAL 072255-001 Apr 15, 1991 DISCN No No   Start Trial   Start Trial   Start Trial
J And J MICRODERM chlorhexidine gluconate SPONGE;TOPICAL 072295-001 Feb 28, 1991 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
McKinsey
Boehringer Ingelheim
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.